From Financial Modeling Prep: 2025-02-27 07:00:12

Barclays maintains an “Overweight” rating for Jazz Pharmaceuticals (NASDAQ:JAZZ), increasing the price target from $190 to $200. Jazz reports record total revenues of $4.1 billion in 2024, driven by key products like Xywav® and Epidiolex®. The approval of Ziihera® for 2L HER2+ (IHC3+) BTC marks a significant milestone for the company’s diversified portfolio.



Read more at Financial Modeling Prep:: Jazz Pharmaceuticals (NASDAQ:JAZZ) Maintains Stron…